Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.

Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.

Detalles Bibliográficos
Autores principales: Rubens, R. D., Kaye, S. B., Soukop, M., Williams, C. J., Brampton, M. H., Harris, A. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977835/
https://www.ncbi.nlm.nih.gov/pubmed/1764386
_version_ 1782135347361087488
author Rubens, R. D.
Kaye, S. B.
Soukop, M.
Williams, C. J.
Brampton, M. H.
Harris, A. L.
author_facet Rubens, R. D.
Kaye, S. B.
Soukop, M.
Williams, C. J.
Brampton, M. H.
Harris, A. L.
author_sort Rubens, R. D.
collection PubMed
description Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.
format Text
id pubmed-1977835
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19778352009-09-10 Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Rubens, R. D. Kaye, S. B. Soukop, M. Williams, C. J. Brampton, M. H. Harris, A. L. Br J Cancer Research Article Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed. Nature Publishing Group 1991-12 /pmc/articles/PMC1977835/ /pubmed/1764386 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Rubens, R. D.
Kaye, S. B.
Soukop, M.
Williams, C. J.
Brampton, M. H.
Harris, A. L.
Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
title Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
title_full Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
title_fullStr Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
title_full_unstemmed Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
title_short Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee.
title_sort phase ii trial of didox in advanced breast cancer. cancer research campaign phase i/ii clinical trials committee.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977835/
https://www.ncbi.nlm.nih.gov/pubmed/1764386
work_keys_str_mv AT rubensrd phaseiitrialofdidoxinadvancedbreastcancercancerresearchcampaignphaseiiiclinicaltrialscommittee
AT kayesb phaseiitrialofdidoxinadvancedbreastcancercancerresearchcampaignphaseiiiclinicaltrialscommittee
AT soukopm phaseiitrialofdidoxinadvancedbreastcancercancerresearchcampaignphaseiiiclinicaltrialscommittee
AT williamscj phaseiitrialofdidoxinadvancedbreastcancercancerresearchcampaignphaseiiiclinicaltrialscommittee
AT bramptonmh phaseiitrialofdidoxinadvancedbreastcancercancerresearchcampaignphaseiiiclinicaltrialscommittee
AT harrisal phaseiitrialofdidoxinadvancedbreastcancercancerresearchcampaignphaseiiiclinicaltrialscommittee

Ejemplares similares